New Wound-Healing Diagnostic System

A fully automated PC-based diagnostic instrument is designed to provide critical information about the health of the microcirculatory system. The system has been cleared by the U.S. Food and Drug Administration (FDA).

Called SensiLase PAD 3000, the skin perfusion pressure (SPP) system is a diagnostic tool for the wound-care market, where it can assess the healing potential and monitor interventional therapy. Also, it may be a good diagnostic tool for the early identification of peripheral arterial disease (PAD), where there has been no easy tool for general screening. With broad usage of SPP and the SensiLase at the early stages of the disease, treatment costs could be reduced due to earlier detection and disease management.

"This product introduction brings the benefits of microvascular assessment using SPP to thousands of wound-care centers in the fast-growing, worldwide wound-care and PAD triage market,” said Paulita LaPlante, president and CEO of Vasamed. "This news positions SensiLase to be the diagnostic and screening tool of choice in its category and serves to extend our record of innovative technology creation in response to an urgent medical need.”

Vasamed is a technology-development company specializing in low-cost, vascular diagnostic systems for noninvasive hemodynamic monitoring.




Related Links:
Vasamed